VIJOICE (alpelisib) is an oral kinase inhibitor primarily used in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS). PROS is a group of disorders characterized by abnormal tissue overgrowth, often associated with mutations in the PIK3CA gene. Alpelisib functions by selectively inhibiting the alpha isoform of phosphoinositide 3-kinase (PI3Kα), an enzyme implicated in the pathogenesis of many cancers and overgrowth syndromes. The drug works by reducing hyperactivity of the PI3K signaling pathway, which helps in controlling abnormal growth and proliferation of affected tissues.

This drug is specifically designed for patients who experience severe manifestations of PROS that cannot be managed with local therapy alone. The treatment is approved based on clinical trial results that showed promising efficacy in reducing the severity and progression of PROS. VIJOICE is administered orally, either in tablet or granule form, with a daily dose tailored according to patient age and response to therapy. It is important for patients to be monitored for potential adverse effects, including severe hypersensitivity, hyperglycemia, and gastrointestinal issues.